drug · protein
tagraxofusp
Phase 2updated 3mo agoby Stemline Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 3 investigational indications.
targets
Elongation factor 2Interleukin-3 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying tagraxofusp
- phase2Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
- phase2Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- phase2A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- phase2A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- phase2Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
- phase2Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
- phase2SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
- phase2Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that